Biacore Analysis of Cross-Reactive Adeno-Associated Virus Antibodies in Monkeys Following Intravenous Administration of AAV5, AAV8, and AAV9 Vectors
Human Gene Therapy · 2025
DOI: 10.1177/10430342251374689 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy, 2025. Verfasst von Yanshan Dai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Myers Squibb Company, Princeton, New Jersey, USA. Hauptthemen laut MEDLINE: Dependovirus, Genetic Vectors, Antibodies, Viral. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
In gene therapy using adeno-associated virus (AAV) vectors, treatment-induced anti-AAV antibodies pose barriers for re-administration of the same or different AAV serotype vectors. We aimed to investigate whether the administration of AAV5, AAV8, or AAV9 in Cynomolgus monkeys resulted in the formation of cross-reactive antibodies. To achieve this, we developed a Biacore SPR-based total binding antibody (TAb) assay to identify anti-AAV antibodies in monkey plasma and assess the cross-reactivity of these antibodies against AAV5, AAV8, or AAV9 vectors on a sensor chip. AAV5, AAV8, and AAV9 vectors were immobilized onto the surface of a CM5 sensor chip on Fc2, Fc3, and Fc4 flow cells, respectively, using amine coupling, while Fc1 served as a reference. Plasma samples flowed through four channels, followed by injecting anti-monkey IgG and IgM antibodies to determine the immunoglobulin (Ig) isotypes. We analyzed TAb against the AAV serotypes in the plasma using a Biacore-based TAb assay 29 days after administration to evaluate the anti-AAV antibody responses. The TAb detected by the Biacore-based assay showed cross-reactivity between antibodies against AAV8 and AAV9; however, there was minimal cross-reactivity between antibodies against AAV5 and those against AAV8 or AAV9. Both IgG and IgM TAb were detected at 29 days post-dosing, and the antibody profiles determined by both the Biacore and ELISA platforms were comparable. The Biacore assessment confirmed the absence of cross-reactivity of anti-AAV5 antibodies against AAV8 and AAV9 vectors, and vice versa. This absence of cross-reactive antibodies against a specific AAV serotype indicated the possibility of re-administering a different AAV serotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bristol Myers Squibb Company, Princeton, New Jersey, USA.
ORCID-Profile: Yanshan Dai
Zitieren
APA
Dai, Y., Banks, G., Wu, G., Levesque, P., Jawa, V., & Kozhich, A. (2025). Biacore Analysis of Cross-Reactive Adeno-Associated Virus Antibodies in Monkeys Following Intravenous Administration of AAV5, AAV8, and AAV9 Vectors. Human Gene Therapy. https://doi.org/10.1177/10430342251374689
Vancouver
Dai Y, Banks G, Wu G, Levesque P, Jawa V, Kozhich A. Biacore Analysis of Cross-Reactive Adeno-Associated Virus Antibodies in Monkeys Following Intravenous Administration of AAV5, AAV8, and AAV9 Vectors. Human Gene Therapy. 2025. doi:10.1177/10430342251374689
BibTeX
@article{Dai2025,
author = {Dai, Yanshan and Banks, Glen and Wu, Grace and Levesque, Paul and Jawa, Vibha and Kozhich, Alexander},
title = {Biacore Analysis of Cross-Reactive Adeno-Associated Virus Antibodies in Monkeys Following Intravenous Administration of AAV5, AAV8, and AAV9 Vectors},
journal = {Human Gene Therapy},
year = {2025},
doi = {10.1177/10430342251374689}
}
EUVIMED